Author: TreatSMA
Roche stops olesoxime development
Roche stops the development of olesoxime, a neuroprotective drug that showed benefit in spinal muscular atrophy.
Biogen responds to the open letter
Biogen responds to the open letter of UK SMA charities regarding SMC recommendation
Open letter to Biogen regarding SMC advice
Open letter to Biogen following SMC recommendation
Update on branaplam progress
Another potential treatment for SMA is progressing fast
Biogen’s statement on the SMC decision
Biogen’s statement re. Scottish decision on nusinersen availability
Breaking news: Scotland refuses to treat majority of people with spinal muscular atrophy
Scotland annouces very restricted access to Spinraza, depriving the majority of SMA patients of an effective treatment
Australia will allocate $240 million to fund Spinraza treatment
Australia will allocate 240 million Australian dollars to fund the break-through Spinraza treatment for those with spinal muscular atrophy.
Update on Spinraza appraisal process
Update on the regulatory appraisal process of Spinraza in England and Wales